Bulletin: BioMark receives $825K grant for its cancer detection technology

Their goal is to develop a low-cost, high-throughput test that will make early-stage lung cancer screening feasible and affordable for at-risk populations.

Jun 7, 2021

∙ Paid

BioMark Diagnostic Solutions Inc. announced that it received $825,000 to develop an early-stage lung cancer screening test using its proprietary liquid biopsy platform. The funding is being provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+), the Canadian Cancer Society, the Canadian Institutes of Health Res…

Bulletin: BioMark receives $825K grant for its cancer detection technology

Their goal is to develop a low-cost, high-throughput test that will make early-stage lung cancer screening feasible and affordable for at-risk populations.

This post is for paid subscribers